Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 5/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.44 |
| ▸ | BCL9 | O00512 | 6/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 6/20 | 0.44 |
| ▸ | TACR2 | P21452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17866256 | 0.88 | CNR1 (0.49) | KDM4ENPC1RAB9ACNR1BCL9 | |
| SCHEMBL2113379 | 0.81 | KDM4E (0.55) | KDM4ENPC1RAB9ACNR1NAMPT | |
| SCHEMBL2112938 | 0.81 | CNR1 (0.57) | CNR1BCL9CTNNB1TACR2 | |
| SCHEMBL10233773 | 0.80 | CNR1 (0.53) | CNR1BCL9CTNNB1TACR2 | |
| SCHEMBL2113194 | 0.80 | CNR1 (0.55) | KDM4ENPC1RAB9ACNR1BCL9 | |
| SCHEMBL2112990 | 0.79 | CNR1 (0.56) | NPC1RAB9ACNR1BCL9CTNNB1 | |
| SCHEMBL12469753 | 0.77 | CNR1 (0.52) | CNR1BCL9CTNNB1TACR2 | |
| SCHEMBL23833492 | 0.72 | KDM4E (0.59) | KDM4ENPC1RAB9ANAMPTGRM1 | |
| SCHEMBL411076 | 0.72 | CNR1 (0.67) | CNR1TACR2 | |
| SCHEMBL12469957 | 0.70 | CNR1 (0.49) | CNR1BCL9CTNNB1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627637-B1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | disclosed |
| US-8410107-B2 | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410107-B2 | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | US | disclosed |
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | APOB, CETP, NPC1L1 | KDM4E 1664/4885NPC1 7/4885RAB9A 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.